SG10201607233TA - Effect of an attenuated bordetella strain against allergic disease - Google Patents

Effect of an attenuated bordetella strain against allergic disease

Info

Publication number
SG10201607233TA
SG10201607233TA SG10201607233TA SG10201607233TA SG10201607233TA SG 10201607233T A SG10201607233T A SG 10201607233TA SG 10201607233T A SG10201607233T A SG 10201607233TA SG 10201607233T A SG10201607233T A SG 10201607233TA SG 10201607233T A SG10201607233T A SG 10201607233TA
Authority
SG
Singapore
Prior art keywords
effect
allergic disease
strain against
bordetella strain
against allergic
Prior art date
Application number
SG10201607233TA
Inventor
Sylvie Claudette Alonso
Rui Li
Camille Locht
Original Assignee
Univ Singapore
Inst Nat Sante Rech Med
Pasteur Institut
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Singapore, Inst Nat Sante Rech Med, Pasteur Institut filed Critical Univ Singapore
Publication of SG10201607233TA publication Critical patent/SG10201607233TA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/235—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Bordetella (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • C07K14/245—Escherichia (G)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/36—Adaptation or attenuation of cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K2039/10—Brucella; Bordetella, e.g. Bordetella pertussis; Not used, see subgroups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/522—Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/577—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 tolerising response

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Cell Biology (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
SG10201607233TA 2011-11-02 2012-11-02 Effect of an attenuated bordetella strain against allergic disease SG10201607233TA (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201161554798P 2011-11-02 2011-11-02

Publications (1)

Publication Number Publication Date
SG10201607233TA true SG10201607233TA (en) 2016-10-28

Family

ID=48192474

Family Applications (2)

Application Number Title Priority Date Filing Date
SG11201401904YA SG11201401904YA (en) 2011-11-02 2012-11-02 Effect of an attenuated bordetella strain against allergic disease
SG10201607233TA SG10201607233TA (en) 2011-11-02 2012-11-02 Effect of an attenuated bordetella strain against allergic disease

Family Applications Before (1)

Application Number Title Priority Date Filing Date
SG11201401904YA SG11201401904YA (en) 2011-11-02 2012-11-02 Effect of an attenuated bordetella strain against allergic disease

Country Status (9)

Country Link
US (1) US9415077B2 (en)
EP (1) EP2773371B1 (en)
CN (1) CN104302314B (en)
AU (1) AU2012331646B2 (en)
CA (1) CA2854110C (en)
DK (1) DK2773371T3 (en)
ES (1) ES2781481T3 (en)
SG (2) SG11201401904YA (en)
WO (1) WO2013066272A1 (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2645190C (en) 2006-03-10 2019-01-15 Institut Pasteur De Lille Live attenuated bordetella strains as a single dose vaccine against whooping cough
SG175803A1 (en) 2009-04-28 2011-12-29 Pasteur Institut Vaccine for prophylaxis or treatment of an allergen-driven airway pathology
DK2773371T3 (en) 2011-11-02 2020-03-09 Nat Univ Singapore EFFECT OF A WEAKENED TABLE TELL STRAIGHT AGAINST ALLERGIC DISEASE
EP2722338A1 (en) 2012-10-17 2014-04-23 INSERM (Institut National de la Santé et de la Recherche Médicale) Novel recombinant Bordetella strains
US9655959B2 (en) 2014-10-01 2017-05-23 National University Of Singapore Adenylate cyclase deficient bordetella strains
SG11201807783UA (en) * 2016-03-29 2018-10-30 Pasteur Institut Mutant bordetella strains and methods for use
CN111278456B (en) * 2017-10-18 2024-08-09 里尔巴斯德研究所 Bao Te strain of genus Bao Te expressing serotype 3 pili
US10973908B1 (en) 2020-05-14 2021-04-13 David Gordon Bermudes Expression of SARS-CoV-2 spike protein receptor binding domain in attenuated salmonella as a vaccine
EP3909971A1 (en) 2020-09-28 2021-11-17 Institute of Life Sciences (ILS) Whole cell livestock vaccine for respiratory diseases

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6713072B1 (en) 1987-11-02 2004-03-30 Chiron S.R.L. Immunologically active polypeptides with altered toxicity useful for the preparation of an antipertussis vaccine
FR2718750B1 (en) 1994-04-19 1996-06-14 Pasteur Institut Recombinant proteins of the filamentous hemagglutinin of Bordetella, in particular, B. Pertussis, production and application to the production of foreign proteins or vaccinating active principles.
FR2754543B1 (en) 1996-10-11 1998-12-31 Pasteur Institut BORDETELLA STRAIN DEFICIENT IN TOXIN PRODUCTION AND EXPRESSING HYDRID PROTEIN, LIPOSOMES COMPRISING FHA AND THEIR USES AS VACCINES, AND THE USE OF FHA TO STIMULATE IMMUNE RESPONSES
FR2840319B1 (en) 2002-05-30 2004-08-20 Pasteur Institut BORDETELLA STRAINS MADE DEFICIENT BY GENETIC ATTENUATION
US7582297B2 (en) 2003-04-11 2009-09-01 Medimmune, Llc Methods of treating respiratory conditions
GB0526031D0 (en) * 2005-12-21 2006-02-01 Bioeos Ltd Use
CA2645190C (en) * 2006-03-10 2019-01-15 Institut Pasteur De Lille Live attenuated bordetella strains as a single dose vaccine against whooping cough
JP2010508860A (en) 2006-11-15 2010-03-25 フォリア バイオテック インコーポレイテッド Influenza vaccine based on papaya mosaic virus
CA2690641A1 (en) 2007-06-18 2008-12-24 Hemispherx Biopharma, Inc. Early intervention of viral infections with immune activators
SG175803A1 (en) 2009-04-28 2011-12-29 Pasteur Institut Vaccine for prophylaxis or treatment of an allergen-driven airway pathology
WO2010146414A1 (en) 2009-06-15 2010-12-23 National University Of Singapore Influenza vaccine, composition, and methods of use
DK2773371T3 (en) 2011-11-02 2020-03-09 Nat Univ Singapore EFFECT OF A WEAKENED TABLE TELL STRAIGHT AGAINST ALLERGIC DISEASE
EP2722338A1 (en) 2012-10-17 2014-04-23 INSERM (Institut National de la Santé et de la Recherche Médicale) Novel recombinant Bordetella strains

Also Published As

Publication number Publication date
DK2773371T3 (en) 2020-03-09
SG11201401904YA (en) 2014-05-29
WO2013066272A1 (en) 2013-05-10
EP2773371A1 (en) 2014-09-10
CA2854110A1 (en) 2013-05-10
CN104302314B (en) 2020-06-02
ES2781481T3 (en) 2020-09-02
AU2012331646A1 (en) 2014-05-22
EP2773371B1 (en) 2020-01-01
AU2012331646B2 (en) 2017-03-30
CN104302314A (en) 2015-01-21
CA2854110C (en) 2019-06-25
US20140271563A1 (en) 2014-09-18
US9415077B2 (en) 2016-08-16
EP2773371A4 (en) 2015-07-01

Similar Documents

Publication Publication Date Title
SG10201607233TA (en) Effect of an attenuated bordetella strain against allergic disease
EP2723384A4 (en) Treatment of proteinopathies
IL229830B (en) Novel compinds as modulatord of gpr-119
EP2717926A4 (en) Compositions and methods to prevent and treat biofilms
EP2670434A4 (en) Treatment of tauopathies
EP2675471A4 (en) Hsa-related compositions and methods of use
HK1202244A1 (en) Prebiotic formulations and methods of use
PL3199024T3 (en) Use of cyclodextrin compositions and methods thereof
EP2717855A4 (en) Methods of treatment
EP2771030A4 (en) Compositions and methods for treatment of proteinopathies
PL2696890T3 (en) Treatment of microbial infections
EP2723347A4 (en) Prevention and treatment of inflammatory conditions
PL2690985T3 (en) Piece of furniture
PL3581199T3 (en) Methods of treatment or reduction of edematous-fibrosclerotic panniculopathy
EP2684164A4 (en) System of evaluating work characteristics and providing worskpace design suggestions
EP2704723A4 (en) Treatment of polycystic disease
SG11201406504XA (en) High elastic modulus shafts and method of manufacture
EP2753337A4 (en) Compositions including beta-glucans and methods of use
EP2670243A4 (en) Compositions and methods for treatment of glaucoma
GB201309274D0 (en) Treatment Of Fuel
EP2774615A4 (en) Agent for increasing amount of muscles
HK1206283A1 (en) Treatment of multiple sclerosis with anti-cd19 antibody -cd19
HK1257401A1 (en) Methods and compositions for the treatment of diabetes and related symptoms
ZA201402437B (en) Diagnosis of tuberculosis
ZA201308101B (en) Diagnostic use of prosomatostatin